Westinghouse has 91 AP1000 units in its order pipeline and a new engineering partner to build them. The Amentum deal, $17.5B in DOE loans and a planned IPO turn nuclear from a licensing problem into a delivery problem.
One hundred million dollars for a company that has yet to disclose a single clinical program. Aureka's bet is that owning the experiment loop beats owning the best algorithm.
Firmus pulled in $2B from Nvidia, Coatue, Blackstone and Jane Street, pushing its valuation past $10.5B in four months. The scarce resource is no longer money. It is the grid.
Vehicle-to-grid left the pilot stage in 2026: GM activated bidirectional charging and E3's study for GM Energy values V2G integration at $7 billion by 2030. Nissan, Enel and Nuvve run the first fully commercial V2G hub in Denmark, and AI-managed aggregation is where the margin forms.
The Coimbra startup monitors 600+ satellites and just raised €15.6M (8M) to add radar, build out the NeuraspaceDEF defence platform, and push its AI toward autonomous orbit management. 350%+ revenue growth and a European ministry mandate make the round worth a look.
Vitestro's Aletta became the first CE-marked autonomous phlebotomy device, drawing blood alone in a Danish clinic in June with a 94.5% first-stick rate across 1,633 Dutch trial patients. It excludes the hard cases, waits on the US FDA, and now sits at the center of DARPA's field-transfusion plans.
KaloCyte's ErythroMer is a freeze-dried artificial red blood cell that needs no refrigeration and works for any blood type. DARPA has put $46 million behind it and targets FDA authorization by 2029. The engineering, the $7 billion market, and what killed every substitute before it.
Velaura AI, the chip designer formerly known as Auradine, closed a $110M Series A valuing the company above $1B. Its Titan Core silicon IP claims a 2-4x performance-per-watt gain for AI accelerators, backed by more than 30 million shipped ASICs. Three scenarios through mid-2027.